Physician profile
Steven Feldman
NPI 1841266905
$6,078.67
in general payments reported to CMS, 2019-2025
28 companies · $921 in 2025
The $921 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $1,041 · 2021: $896 · 2022: $922 · 2023: $828 · 2024: $549 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.75 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,537.05 | 2019-2025 | Evenity, Prolia, Prolia |
| Ucb, INC. | $797.14 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $647.98 | 2019-2025 | |
| Glaxosmithkline, LLC. | $585.52 | 2019-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $345.70 | 2019-2025 | Tremfya |
| Radius Health, INC. | $342.16 | 2019-2023 | Tymlos |
| Aurinia Pharma U.S., INC. | $263.27 | 2021-2025 | Lupkynis |
| Pfizer INC. | $215.78 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $166.02 | 2020-2024 | Acthar |
| Genzyme Corporation | $142.88 | 2025 | |
| Lilly USA, LLC | $110.65 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $107.89 | 2023-2025 | Purified Cortrophin Gel |
| Alvogen INC | $96.73 | 2022-2025 | Teriparatide |
| Johnson & Johnson Health Care Systems INC. | $94.31 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $81.23 | 2019-2023 | Saphnelo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $69.70 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $65.62 | 2019-2021 | |
| Horizon Therapeutics Plc | $64.71 | 2020-2023 | Krystexxa |
| Genentech USA, INC. | $49.26 | 2019-2022 | |
| Avion Pharmaceuticals | $45.60 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $44.47 | 2024 | Arcalyst |
| Organon LLC | $39.20 | 2025 | Hadlima |
| Fresenius Kabi USA, LLC | $35.64 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.01 | 2022 | |
| Celgene Corporation | $30.47 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.57 | 2021 | |
| Hikma Pharmaceuticals USA | $20.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.